FDA Approves ONUREG — Celgene Corporation

# FDA Approves Celgene's ONUREG (Azacitidine) as First Oral Maintenance Therapy for AML The FDA approval of Celgene Corporation's ONUREG (azacitidine) marks a significant market opportunity as the first and only oral azacitidine maintenance treatment for acute myeloid leukemia, potentially capturing share from intravenous alternatives and expanding the addressable market among patients seeking improved convenience and quality of life. The oral formulation is expected to strengthen Celgene's hematology-oncology portfolio and drive incre